Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Chronic Kidney Disease
100%
Dapagliflozin
96%
Placebo
37%
Albuminuria
30%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
27%
Type 2 Diabetes Mellitus (T2DM)
25%
Urinary Albumin-to-creatinine Ratio
25%
Estimated Glomerular Filtration Rate
24%
Kidney
21%
Type 2 Diabetic Patients
20%
Diabetic Kidney Disease
20%
Adverse Outcomes
19%
Composite Endpoint
19%
95% Confidence Interval
19%
DAPA-CKD
16%
Hazard Ratio
16%
Canagliflozin
16%
Finerenone
16%
Cardiovascular Mortality
15%
Diabetes
15%
Kidney Failure
14%
Kidney Outcomes
14%
Kidney Disease Progression
13%
Estimated Glomerular Filtration Rate Slope
12%
Treatment Effect
11%
Without Diabetes
10%
Nephropathy
10%
Clinical Evaluation
10%
Clinical Trials
9%
Hemoglobin A1c (HbA1c)
9%
Heart Failure Hospitalization
8%
Estimated Glomerular Filtration Rate Decline
7%
Renal Events
7%
Hierarchical Composites
7%
Meta-analysis
7%
Heart Failure
7%
All-cause Mortality
7%
Cardiovascular Outcomes
7%
Evaluation Trial
7%
Win Odds
7%
Hospitalization
6%
Randomized Controlled Trial
6%
Glomerular Filtration Rate
6%
Randomized Placebo-controlled Trial
6%
Focal Segmental Glomerulosclerosis
6%
IgA Nephropathy (IgAN)
6%
Eplerenone
6%
End-stage Kidney Disease
6%
Randomized Crossover
6%
Blood Pressure
6%
Medicine and Dentistry
Chronic Kidney Disease
83%
Dapagliflozin
73%
Glomerular Filtration Rate
42%
Cardiovascular System
35%
Placebo
31%
Urinary System
25%
Albumin
21%
Creatinine
20%
Nephropathy
19%
Maturity Onset Diabetes of the Young
17%
Clinical Trial
17%
Albuminuria
16%
Adverse Outcome
15%
Finerenone
13%
Diabetes
12%
Renal Failure
11%
Post-Hoc Analysis
11%
Hazard Ratio
11%
Treatment Effect
11%
Congestive Heart Failure
10%
Kidney Function
10%
Patient with Type 2 Diabetes
9%
Randomized Controlled Trial
7%
Sodium Glucose Cotransporter 2 Inhibitor
7%
Disease Exacerbation
7%
Adverse Event
6%
Immunoglobulin A Nephropathy
6%
End Stage Renal Disease
6%
Clinical Trial Design
6%
Eplerenone
6%
Biological Marker
5%
All Cause Mortality
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
73%
Dapagliflozin
73%
Placebo
43%
Maturity Onset Diabetes of the Young
34%
Creatinine
30%
Albumin
28%
Albuminuria
28%
Clinical Trial
26%
Kidney Disease
24%
Canagliflozin
17%
sodium glucose cotransporter-2 inhibitors
16%
Kidney Failure
16%
Adverse Outcome
15%
Congestive Heart Failure
14%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Hemoglobin A1c
10%
Adverse Event
10%
Finerenone
8%
Disease Exacerbation
6%
Randomized Controlled Trial
6%
Controlled Clinical Trial
6%
Atrasentan
6%
Mineralocorticoid Antagonist
6%
Sodium Glucose Cotransporter 2
6%
Focal Glomerulosclerosis
6%
Semaglutide
6%
Obesity
5%
